acute ischemic stroke
Conditions
Interventions
The standard treatment group:The standard treatment group
The adenosine treatment group:Adjunctive Intra-arterial adenosine following Successful Endovascular Thrombectomy
Sponsors
The First Affiliated Hospital of Army Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1.Aged >= 18 years; 2.The time from onset to randomization was within 24 hours; 3. Large vessel occlusive stroke in the anterior circulation confirmed by CTA/MRA/DSA (Including intracranial segment of internal carotid artery and M1 or M2 segment of middle cerebral artery) and the vessel responsible for the signs and symptoms of acute ischemic stroke; 4. NIHSS score on admission >= 6 and <= 25; 5.Successful endovascular thrombectomy (eTICI 2b50-3); 6.Written informed consent signed by patients or their family members;
Exclusion criteria
Exclusion criteria: 1.Intracranial hemorrhage confirmed by cranial computed tomography (CT) or magnetic resonance imaging (MRI); 2.Prestroke mRS score >= 2; 3. Intraoperative DSA angiography suggests vessel penetration, entrapment, and extravasation of contrast medium; 4.Pregnant or lactating patients; 5.Allergic to contrast agents or Adenosine; 6.Degree II or III atrioventricular block or sick sinus syndrome (except for patients with artificial pacemakers); 7.Patients with known or estimated pulmonary disease with bronchial stenosis or bronchospasm (e.g., asthma); 8.Systolic blood pressure>185mmHg or diastolic blood pressure>110mmHg, and cannot be well controlled by oral antihypertensive drugs; 9.Blood glucose 22.2 mmol/L (400 mg/dl); 10.Known bleeding tendency (including but not limited to): coagulation factor deficiency disease or platelets 3.0; 11. Patients on chronic hemodialysis and severe renal insufficiency (glomerular filtration rate 220 µmol/L (2.5mg/dl)); 12.Any terminal illness with a life expectancy of less than 6 months; 13.History of intracranial hemorrhage in the last 1 month; 14.Intracranial aneurysm, arteriovenous malformation; 15.Brain tumors with occupying effect on imaging; 16.Unlikely to be available for 90-day follow-up; 17.Current participation in another clinical trial;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Shift in the distribution of mRS scores at 90 days;The change of the NIHSS score at 5–7days or discharge if earlier from baseline; | — |
Secondary
| Measure | Time frame |
|---|---|
| Proportion of mRS score 0 to 1 at 90 days;Proportion of mRS score 0 to 2 at 90 days;Proportion of mRS score 0 to 3 at 90 days;European Quality Five-Dimension scale score at 90 days;symptomatic intracranial hemorrhage (sICH) within 48 h;mortality at 90 days; | — |
Countries
China
Contacts
Public ContactZhenhua Zhou
The First Affiliated Hospital of Army Medical University
Outcome results
None listed